 |
|
|
| |
HARNESS study: ritonavir-boosted atazanavir
(ATV/r)+raltegravir (RAL) switch study in virologically suppressed, HIV-1-infected patients
|
| |
| |
Reported by Jules Levin
20th International AIDS Conference, Melbourne, Australia, July 20Đ25, 2014
J. van Lunzen1, A. Pozniak2, J. Gatell3, A. Antinori4, I. Klauck5, O. Serrano6, A. Baakili5,7, M. Yu8, P-M. Girard9
1University Medical Center Hamburg-Eppendorf, Infectious Diseases Unit, Hamburg, Germany; 2Chelsea and Westminster Hospital, London, United Kingdom; 3Infectious Diseases & AIDS Units, Clinical Institute of Medicine & Dermatology, Hospital Clinic, University of Barcelona, Barcelona, Spain; 4National Institute for Infectious Diseases, Rome, Italy; 5Bristol-Myers Squibb, Rueil-Malmaison, France; 6Bristol-Myers Squibb, Madrid, Spain; 7Bristol-Myers Squibb, Uxbridge, United Kingdom; 8Bristol-Myers Squibb, New York, New York, USA, 9Service des Maladies Infectieuses, H™pital St Antoine, APHP, Paris. France
|
| |
|
|
|
|
|
